Tagged with r&d

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has with France, general manager Jerome Bouyer offers an optimistic view of how the French healthcare sector can best be structured…

Pharma Elena Tremoli, Scientific Director at Centro Cardiologico Monzino, explains the importance of both applied and cardiovascular research in Italy, and how prevention in this area will be key in the future. Centro Cardiologico Monzino is the only institute of excellence in Europe exclusively devoted to cardiovascular diseases. Can you describe…

Pharma Pharmaceuticals Mauritius’s economic stability, genetic diversity, cost competitiveness, and location make it a perfect location for clinical research; a fact the state is now actively promoting. A further vision of the Mauritian government is to transform the island into a medical hub for clinical research. Besides political and economic stability, a number of…

Pharma Pharmaceuticals Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened: you were made European CEO in 2015 for having steered Dompé through considerable renewal and restructuring, the company also embarked…

Pharma Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international footprint; and how their ambition is to grow from total revenues of 4 billion euros (4.46 billion USD) today, to…

Pharma Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director  Bernat Albinyana discusses the affiliate’s performance, its business organization and commitment to R&D, as well as its grand ambitions for the next few years. In 1986, Italy was…

Pharma The chairman of Egypt’s largest holding company for pharmaceutical manufacturers, ACDIMA, shares his vision for how Egyptian manufacturers can enhance their competitiveness in the coming years, and extend their activities further up the value chain into API production and R&D activities. How well prepared are Egyptian companies to compete in…

Pharma Puerto Rico is starting to move towards greater R&D activity. World class research centers in cardiovascular, oncology, and soon molecular science are putting the territory on the global map for pharmaceutical research. But Puerto Rico is starting to move beyond manufacturing and towards greater R&D activity. Puerto Rico’s Cardiovascular and…

Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…

Pharma Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region offers and the services the institution has to help companies go international. Could you please explain the reasons behind the…

Pharma Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D printing, explains how his company aims to provide patients worldwide with the tailor-made implants they deserve while reducing the overall socio-economic cost…